Home/LENZ Therapeutics/Dan Chevallard

DC

Dan Chevallard

Chief Financial Officer

LENZ Therapeutics

Therapeutic Areas

Ophthalmology Refractive Disorders

LENZ Therapeutics Pipeline

Drug	Indication	Phase
VIZZ™ (aceclidine ophthalmic solution) 1.44%	Presbyopia	Approved
LNZ101 (aceclidine/brimonidine)	Presbyopia	Phase 3

Leadership Team at LENZ Therapeutics

Eef Schimmelpennink

President and Chief Executive Officer

Chief Commercial Officer

Chief Medical Officer

SVP, Regulatory and Clinical Operations

View full LENZ Therapeutics profile